返回
Evommune Inc（EVMN）價格
EVMN 股價走勢圖
EVMN 財務
Evommune Inc
$31.57
13.23%
$3.69
收盤價：Feb 13, 16:00:00 GMT-5
$32.09
1.64%
$0.52
盤後：Feb 13, 20:00:00 GMT-5
關鍵數據
前收市價
$27.88
開盤價
$29.71
當日範圍
$29.1 - $32.98
52週區間
$13.88 - $33.2
交易量
1.3M
平均成交量
534.9K
每股盈餘 (TTM)
-5.08
股息收益率
--
市值
$1.0B
什麼是 EVMN？
Evommune, Inc. is a clinical-stage biotechnology company. The company is headquartered in Palo Alto, California and currently employs 45 full-time employees. The company went IPO on 2025-11-06. Its initial clinical development programs are focusing on chronic spontaneous urticaria (CSU), atopic dermatitis (AD) and ulcerative colitis (UC). Its product candidates include EVO756 and EVO301. The firm's advanced clinical-stage product candidate, EVO756, is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor predominantly found on mast cells and peripheral sensory neurons, which is initially being evaluated in Phase II trials for the treatment of CSU and AD. The firm's second clinical-stage product candidate, EVO301, is a long-acting fusion protein consisting of an IL-18 binding protein (BP) and an anti-serum albumin Fab-associated (SAFA) domain, which is being evaluated in Phase II trials for the treatment of AD and UC.